THE EFFECT OF LENVATINIB AND PEMBROLIZUMAB ON THYROID CANCER REFRACTORY TO IODINE 131I SIMULATED BY MATHEMATICAL MODELING

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorInstituto Federal de Mato Grosso (IFMT)-
Autor(es): dc.contributorUniversidade de Brasília (UnB)-
Autor(es): dc.contributorInstitute Camille Jordan-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorSilva, Jairo Gomes da-
Autor(es): dc.creatorSilva, Izabel Cristina Rodrigues da-
Autor(es): dc.creatorAdimy, Mostafa-
Autor(es): dc.creatorMancera, Paulo Fernando De Arruda-
Data de aceite: dc.date.accessioned2025-08-21T20:46:44Z-
Data de disponibilização: dc.date.available2025-08-21T20:46:44Z-
Data de envio: dc.date.issued2023-03-01-
Data de envio: dc.date.issued2023-03-01-
Data de envio: dc.date.issued2022-03-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1142/S0218339022500036-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/239935-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/239935-
Descrição: dc.descriptionImmunotherapy and targeted therapy are alternative treatments to differentiated thyroid cancer (DTC), which is usually treated with surgery and radioactive iodine. However, in advanced thyroid carcinomas, molecular alterations can cause a progressive loss of iodine sensitivity, thereby making cancer resistant to radioactive iodine-refractory (RAIR). In the treatment of cancer, tyrosine kinase inhibitors are administered to prevent the growth of cancer cells. One such inhibitor, lenvatinib, forms a targeted therapy for RAIRDTC, while the immunotherapeutic pembrolizumab, a humanized antibody, prevents the binding of programmed cell death ligand 1 (PD-L1) to the PD-1 receptor. As one of the first studies on treatments for thyroid cancer with mathematical model involving immunotherapy and targeted therapy, we developed an ordinary differential system and tested variables such as concentration of lenvatinib and pembrolizumab, total cancer cells, and number of immune cells (i.e., T cells and natural killer cells). Analyzing local and global stability and the simulated action of drugs in patients with RAIR-DTC, revealed the combined effect of the targeted therapy with pembrolizumab. The scenarios obtained favor the combined therapy as the best treatment option, given its unrivaled ability to boost the immune system's rate of eliminating tumor cells.-
Descrição: dc.descriptionInstituto Federal de Mato Grosso (IFMT), Campus de Barra do Garças, MT-
Descrição: dc.descriptionFaculdade de Ceilândia Universidade de Brasilia (UnB), Ceilândia Sul, DF-
Descrição: dc.descriptionINRIA Univ Lyon Université de Lyon 1 Institute Camille Jordan, 43 Bd. du 11 novembre 1918-
Descrição: dc.descriptionUniversidade Estadual Paulista (UNESP) Instituto de Biociências, SP-
Descrição: dc.descriptionUniversidade Estadual Paulista (UNESP) Instituto de Biociências, SP-
Formato: dc.format93-112-
Idioma: dc.languageen-
Relação: dc.relationJournal of Biological Systems-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAsymptotic Stability-
Palavras-chave: dc.subjectImmune System-
Palavras-chave: dc.subjectImmunotherapy-
Palavras-chave: dc.subjectLyapunov Function-
Palavras-chave: dc.subjectMathematical Model-
Palavras-chave: dc.subjectTargeted Therapy-
Palavras-chave: dc.subjectThyroid Tumor-
Título: dc.titleTHE EFFECT OF LENVATINIB AND PEMBROLIZUMAB ON THYROID CANCER REFRACTORY TO IODINE 131I SIMULATED BY MATHEMATICAL MODELING-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.